Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 46.28
+1.23 (2.73%)
Oct 23, 2026, 3:00 PM CST
SHA:688513 Market Cap
SHA:688513 has a market cap or net worth of 8.03 billion as of October 22, 2026. It is the 9,203rd most valuable company in the world and the 1,925th biggest in China. Its market cap has decreased by 12.48% in one year.
Market Cap
8.03B
Enterprise Value
6.60B
Revenue
1.34B
Global Rank
Country Rank
#1,925 China
PE Ratio
28.92
ChartMarket Cap Chart
Since September 2, 2020, SHA:688513's market cap has decreased from 8.97B to 8.03B, a decrease of -10.48%. That is a compound annual growth rate of -1.79%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 23, 2026 | 8.03B | -25.15% |
| Dec 31, 2025 | 10.73B | 104.34% |
| Dec 31, 2024 | 5.25B | -31.43% |
| Dec 29, 2023 | 7.66B | 4.83% |
| Dec 30, 2022 | 7.31B | 31.12% |
| Dec 31, 2021 | 5.57B | -2.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 2, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| InventisBio | 8.97B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 8.85B |
| Chongqing Genrix Biopharmaceutical | 8.58B |
| Shanghai OPM Biosciences | 8.41B |
| Liaoning Chengda Biotechnology | 8.30B |
| Vcanbio Cell & Gene Engineering Corp., | 8.15B |
| Novogene | 7.96B |
| Jiangxi Fushine Pharmaceutical | 7.88B |